Contract Deobligations Alert — September 23, 2026

MetGreen secured a firm-fixed-price delivery order with a base-plus-all-options ceiling of $871.5 million, establishing a predictable revenue stream of ~$97.4 million annually through 2027. The SDVOSB set-aside provides competitive insulation but limits TAM to set-aside slots.

Regeneron's cost-sharing contract reduces its financial risk while $236.3 million already outlayed signals strong execution and cash flow. Potential extension to $359.6 million through 2027 aligns with sustained biodefense priorities.

Booz Allen's cost-plus award fee contract for Mission IT systems development provides predictable margins and low financial risk, with a total potential value of $379.6 million. Full-and-open competition win affirms its competitive position against other large integrators.

Only $79.5 million of the $192.3 million firm-fixed-price contract has been outlayed, with no contract options or extensions beyond September 2026. The one-year duration and high fixed-price execution risk demand close monitoring of outlay velocity.

The VA accounts for $581.8 million (55%) of total digest value across two contracts (MetGreen and OptumServe). Any VA budget cuts or procurement policy shifts would disproportionately affect these contractors.

OptumServe's $192.3M firm-fixed-price contract with a one-year duration and only 41% outlayed carries high execution risk if costs exceed fixed estimates or if the VA delays task order funding.

MetGreen's SDVOSB set-aside status limits its long-term growth vector to set-aside opportunities, and its small size relative to the $389.5M contract raises doubts about execution capacity and margin stability. Re-compete in 2027 could attract larger players.

The Booz Allen Hamilton contract (2016 award, 2021 completion) has a negative outlayed amount (-$58,816), suggesting prior period adjustments or disputed costs. GSA FEDSIM budget reauthorization cycles could impact follow-on awards.

Booz Allen's GSA FEDSIM win for Mission IT systems development positions it to capture additional DOD and civilian agency IT modernization work, especially as GSA expands its shared services model.

MetGreen's $389.5M ServiceNow contract signals the VA's appetite for cloud-based IT platforms. ServiceNow (NOW) and its implementation partners could see sustained demand for licenses and deployment services across civilian agencies.

MetGreen's SDVOSB contract demonstrates set-aside programs can deliver material revenue. Investors should watch for other SDVOSB-eligible IT contracts at VA and HHS for similar-sized awards.

MetGreen's $389.5M ServiceNow license award confirms the VA is prioritizing cloud-based IT service management platforms. This aligns with broader federal IT modernization initiatives under the Technology Modernization Fund and FITARA.

Regeneron's $278.8M cost-sharing contract with HHS/BARDA demonstrates ongoing government commitment to pandemic preparedness and monoclonal antibody development, even as COVID-era emergency spending normalizes.

OptumServe's $192.3M one-year contract for medical evaluations underscores the VA's reliance on third-party providers for disability and screening services, but the fixed-price structure and short duration increase execution risk for contractors.

{"entity" => "MetGreen Solutions Inc.", "reason" => "High materiality ($389.5M) SDVOSB contract drives significant revenue concentration risk. Monitor its ability to service the $871.5M ceiling and any re-compete activity in 2027.", "trigger" => "VA ServiceNow re-compete RFP release, MetGreen financial reporting, SDVOSB status verification"}

{"entity" => "OptumServe / UnitedHealth Group (UNH)", "reason" => "Only 41% of $192.3M contract outlayed; low outlay rate could signal performance issues or funding delays at VA.", "trigger" => "Obligation modification on FedBizOpps, VA funding lapse, contract termination notice"}

{"entity" => "Booz Allen Hamilton Inc.", "reason" => "GSA FEDSIM contract ended 2021; negative outlayed amount needs clarification. Watch for follow-on GSA Mission IT awards.", "trigger" => "GSA FEDSIM new OASIS or Alliant 2 task order awards, Booz Allen quarterly filings"}

{"entity" => "Regeneron Pharmaceuticals Inc.", "reason" => "$80.8M unexercised option value remains on table; BARDA policy shifts under new administration could affect biodefense funding.", "trigger" => "BARDA option exercise notice, NDAA biodefense funding levels, Regeneron 10-K revenue recognition"}